Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Feb 23;32(3):184.
doi: 10.1007/s00520-024-08385-7.

Acute cancer-related symptoms and concerns among patients receiving chemotherapy: current state of the science

Kristen S Smith  1 , Aasha I Hoogland  2 , Taylor Welniak  2 , Oanh L Nguyen  2 , Yvelise Rodriguez  2 , Xiaoyin Li  2 , Sylvia L Crowder  2 , Laura B Oswald  2 , Kristen M Carpenter  3 , Stacy M Fischer  4 , Daneng Li  5 , Anita Y Kinney  6 , Donna L Berry  7 , Brian D Gonzalez  2 , Heather S L Jim  2
Affiliations
Observational Study

Acute cancer-related symptoms and concerns among patients receiving chemotherapy: current state of the science

Kristen S Smith et al. Support Care Cancer. .

Abstract

Purpose: This study provides an updated evaluation of the prevalence and severity of acute cancer-related symptoms and quality of life (QOL) concerns among patients treated with emetogenic chemotherapy.

Methods: Patients were recruited to a larger, multi-site observational study prior to starting chemotherapy. Participants completed sociodemographic questionnaires and clinical data were abstracted via medical record review. Symptoms and QOL were assessed 5 days after starting moderately or highly emetogenic chemotherapy. Functional Assessment of Cancer Therapy - General assessed QOL concerns. Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events evaluated symptoms. Symptoms were considered severe when participants responded "severe" or "very severe."

Results: Participants (N = 1174) were on average 58 ± 13 years, mostly female (73%), non-Hispanic (89%), and White (87%). Most participants were diagnosed with breast (38.1%), gynecological (20%), and gastrointestinal (17.1%) cancer. The most common QOL concerns of any severity were fatigue (94%), anhedonia (89%), dissatisfaction with QOL (86%), and sleep disturbance (86%). The most common severe QOL concerns were anhedonia (44%), fatigue (40%), and inability to work (38%). Decreased appetite (74%), pain (71%), and constipation (70%) were the most common symptoms of any severity, as well as most common severe symptoms (13%, 18%, and 18%, respectively).

Conclusion: Herein, updates are provided in regard to QOL concerns and symptoms reported by patients in the days after chemotherapy and demonstrates that concerns and symptoms have shifted in the last decade.

Keywords: Chemotherapy-induced nausea; Emetogenic chemotherapy; Fatigue; Patient-reported outcomes; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Competing interests Brian Gonzalez – paid consultant for SureMed Compliance outside this work and advisor for Elly Health outside this work. Heather Jim – paid consultant for SBR Bioscience and Kite Pharma outside of this work. All other authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Responses of patients undergoing moderately to highly emetogenic chemotherapy to Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) severity items
See this image and copyright information in PMC

References

    1. Haiderali A, Menditto L, Good M et al. (2011) Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 19(6):843–51 - PubMed
    1. Jacobs JM, Ream ME, Pensak N et al. (2019) Patient experiences with oral chemotherapy: adherence, symptoms, and quality of life. J Natl Compr Canc Netw 17(3):221–228 - PMC - PubMed
    1. Jordan K, Aapro M, Kaasa S et al. (2018) European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol 29(1):36–43 - PubMed
    1. Von Ah D, Brown CG, Brown SJ, Bryant AL, Davies M, Dodd M, Ferrell B, Hammer M, Knobf MT, Knoop TJ, LoBiondo-Wood G, Mayer DK, Miaskowski C, Mitchell SA, Song L, Watkins Bruner D, Wesmiller S, Cooley ME (2019) Research agenda of the oncology nursing society: 2019–2022. Oncol Nurs Forum 46(6):654–669. 10.1188/19.ONF.654-669 - DOI - PubMed
    1. Knobf M, Cooley ME, Duffy S, et al. The 2014–2018 Oncology Nursing Society research agenda. In: Oncology nursing forum, 2015: Abstract 42, p. 450–465 - PubMed

Publication types

LinkOut - more resources